GnRHa flare and IVF pregnancy rates

International Journal of Gynecology and Obstetrics

Volumn 85, Issue 1, 2004, Pages 36-39

  Confino, E ^a   Zhang, X ^a   Kazer, R R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Flare; High dose gonadotropin treatment; IVF

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST;

ADULT; ARTICLE; CHI SQUARE TEST; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESPONSE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARY; OVARY FOLLICLE MATURATION; PREGNANCY RATE; PRIORITY JOURNAL; STUDENT T TEST;

EID: 1842424515     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(03)00344-8     Document Type: Article

References (15)

1. Van Rysselberge M., Puissant F., Barlow P., et al. Fertility prognosis in IVF treatment of patients with cancelled cycles. Hum Reprod. 4:1989;663-666.
2. Jenkins J.M., Davies D.W., Devonport H., et al. Comparison of 'poor' responders with 'good' responders using a standard buserelin/human menopausal gonadotropin regime for in vitro fertilization. Hum Reprod. 6:1991;918-921.
3. Karande V., Gleicher N. A rational approach to the management of low responders in in vitro fertilization. Hum Reprod. 14:1999;1744-1748.
4. Pellicer A., Lightman A., Diamond M.P., et al. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril. 47:1987;812-815.
5. Van Hooff M.H., Alberda A.T., Huisman G.J., et al. Doubling the human menopausal gonadotropin dose in the course of an in vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod. 8:1993;369-373.
6. Karande V.C., Jones G.S., Veeck L.L., et al. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low responder patients. Fertil Steril. 53:1990;486-494.
7. Feldman B., Seidman D.S., Levron J., Bider D., Shulman A., Shin S., Dor J. In vitro fertilization following natural cycles in poor responders. Gynecol Endocrinol. 15:2001;328-334.
8. Dor J., Seidman D.S., Amudai E., et al. Adjuvant growth hormone therapy in poor responders to in vitro fertilization: a prospective randomized placebo-controlled double-blind study. Hum Reprod. 10:1995;40-43.
9. Akman M.A., Erden H.F., Tosun S.B., et al. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod. 15:2000;2145-2147.
10. Brown J.R., Liu H.C., Sewitch K.F., et al. Variability of day 3 follicle-stimulating hormone levels in eumenorrheic women. J Reprod Med. 40:1995;620-624.
11. Scott R.T. Jr., Hofmann G.E., Oehninger S., et al. Intercycle variability of day 3 follicle stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril. 54:1990;297-302.
12. Karande V., Morris R., Rinehart J., et al. Limited success using the 'flare' protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization. Fertil Steril. 67:1997;900-903.
13. Albano C., Smitz, Tournaye H., et al. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod. 14:1999;1426-1430.
14. Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist Ganirelix (org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 13:1998;3023-3031.
15. Surrey E.S., Schoolcraft W.B. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 75:2001;226-227.